Masitinib for the treatment of locally advanced or metastatic pancreatic cancer
Status Suspended
Process STA pre-2018
Topic area
  • Cancer
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: 12 November 2013
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Project manager:

Bijal Joshi

Technical Lead: Rosemary Lovett


Key events during the development of the guidance:

Date Update
10 July 2014

On 24 Jan 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for masitinib. Following a re-examination of the opinion, at the request of the applicant, a further refusal of the marketing authorisation was given on 27 May 2014.

Therefore, the appraisal of masitinib for treating locally advanced or metastatic pancreatic cancer [ID566] has been suspended indefinitely on the technology appraisals work programme.

04 February 2014

Please note that the manufacturer has informed NICE that they will not provide an evidence submission on the date requested, therefore we are temporarily suspending the appraisal whilst we consider the next steps.

Therefore, the Committee Meeting will note take place 23 April 2014

03 May 2013 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance